3SBio Inc. , a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, announced that Dr. Yingfei Wei, Chief Scientific Officer, will present at the Piper Jaffray 20th Annual Health Care Conference in New York on Tuesday, December 2, 2008 at 11:00AM .
3SBio Inc. , a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the third quarter ended September 30, 2008.
3SBio Inc. , a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has filed with the Chinese State Food and Drug Administration for approval of NuLeusin for the treatment of late stage metastatic renal cell carcinoma.
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Ramifications from the worldwide economic crisis continued to seep into the world of China biotech last week. Most notably, Charles River Labs (CRL) noted that more and more of its contract research clients are postponing scheduled studies into next year (see story). Other clients, aware of their own tight budgets and increased capacity in the CRO industry worldwide, are aggressively seeking price reductions. The trend caused no more than a slowdown in growth in Charles River’s Q3. But for Q4, the effect will...
3SBio Inc. (SSRX) announced a $2.7 million writedown as a consequence of the U.S. financial crisis. The company invested in $3 million of Floating Rate Notes due January 21, 2009 that are subject to the credit of Lehman Brothers. As a consequence of the Lehman Brothers bankruptcy, the notes have been given a value of $300,000. The notes were credit default swaps issued by UBS AG, and they are linked to credit of Lehman Brothers Holdings Inc.
Stories about new deals, drug development and financial news showed that China biophama continued its evolution last week. Phynova (PHNVY.PK) was a prominent example. The UK-based botanical drug company announced that it has adopted a more China-centric focus (see story). Traditionally, the company has always had a connection to China; it owns a 45% share in Botanic Century Beijing Ltd, a drug development company, and its previous business plan called for the use of TCM formulations as a basis for drugs that addressed unmet...
3SBio Inc. (SSRX) has filed for SFDA approval of a high-dose, 36,000 IU formulation of EPIAO for the treatment of anemia resulting from chemotherapy. Unlike 3SBio’s other formulations of EPO, this one would be exclusive to the company. A 36,000 IU injection would be administered once every week, a significant advantage over the three-times per week administration of the more common 10,000 IU injections.
In its clinical trial, the high-dose EPIAO performed at about the same levels as the low-dose formulation. In both cases,...
Last week was a big week for earning announcements from China life science enterprises: a total of eight companies announced their results. Earnings reports far overshadowed almost any other kind of news from the China life sciences sector. For the most part, the eight companies posted incredible increases in revenues, though many times each enterprise’s net income was not as spectacular. Perhaps this is the adolescent phase of China biopharma development: spectacular growth spurts, but often accompanied around the edges by adjustment difficulties as young...
3SBio Inc. (SSRX) reported that Q2 revenue increased 38% to 60 million RMB ($8.7 million), but net income actually declined 17% to 19 million RMB ($2.2 million). That number works out to earnings of 13 cents per ADS. The company took advantage of the higher sales numbers to raise its full-year 2008 revenue targets by about $4 million to a range of $34 million to $35 million.
Net margin for Q2 of 2008 was 32.5% as compared...
There are 6 key Chinese and Hong Kong ADRs within the GICS healthcare sector: Mindray Medical International (MR), Chine Medical Technologies (CMED), Wuxi PharmaTech (WX), Simcere Pharmaceutical (SCR), 3SBio (SSRX), and Tongjitang Chinese Medicines (TCM)
July was a volatile month for the U.S. markets. The Dow Jones Industrial Average started the month with some big losses, even closing below 11,000 for the first time in two years on July 15th. But since then, the index has reclaimed some of the losses after a pair of strong rallies, fueled by declining oil price. For the month, the Dow rose a meager 0.25%, the NASDAQ rose 1.42% and the broader S&P 500 index declined just about 1%.
During the month, the Shanghai Composite Index (^SSEC) showed some signs of life, briefly going...
SHENYANG, China , Nov. 24 /PRNewswire/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products ...
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and ...
3SBio Inc. Trading Markets (press release) - Nov 14, 2008
Nov 14, 2008 (Zacks Investment Research via COMTEX) -- SSRX | Quote | Chart | News | PowerRating -- 3SBio Inc. is a fully integrated, China-based leading biotechnology company focused on ...
SHENYANG, China , Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. SSRX ("3SBio" or the "Company"), a leading China -based biotechnology company focused on researching, developing ...
SHENYANG, China, Nov. 10 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical ...
3SBio Inc. (NSDQ: SSRX) announced a $2.7 million writedown as a consequence of the US financial crisis. The company invested in $3 million of Floating Rate Notes due January 21, 2009 that are ...
NEW YORK (MarketWatch) -- With Acorn International and Qiao Xing Mobile out of the gate last week, a steady stream of initial public offerings from China are drawing support on Wall Street, with others likely to follow.
NEW YORK (MarketWatch) -- Led by a strong performance from hedge fund manager Fortress Investment Group, the crop of U.S. initial public offerings raised 18% more money in the first quarter, tipping the scales at nearly $12 billion.
NEW YORK (MarketWatch) -- A pair of Chinese companies diverged in their stock market debuts on Wednesday after both priced above their estimated ranges.
SAN FRANCISCO (MarketWatch) -- U.S.-listed shares of overseas companies moved higher Wednesday, with chipmaker Infineon Technologies topping percentage gainers after it won a contract from Nokia Corp. and China's JA Solar Holdings Co. turning in a strong performance on its first day of trading.
NEW YORK (MarketWatch) -- 3SBio Inc. priced 7.7 American depositary shares at $16 a share in a bid to raise $123 million its initial public offering on Wednesday. The biotech company priced above its $12-$14 range with underwriters UBS Investment Bank, CIBC World Markets Corp and Pacific Growth Equities LLC.
NEW YORK (MarketWatch) -- 3SBio Inc., a China-based drug maker, late Friday filed to raise up to $124 million in an initial public offering of American depositary shares with underwriter UBS Investment Bank . The company plans to trade on the Nasdaq under the symbol SSRX. 3SBio Inc. plans to offer 7.7 million American depositary shares at an estimated price range of $12-$14 each.
Stocks 
3SBio Inc. (SSRX) 
